PegBio Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PegBio Co., Ltd. - overview
Established
2008
Location
Hangzhou, Zhejiang, China
Primary Industry
Pharmaceuticals
About
Founded in 2008 and based in Suzhou, China, PegBio Co. , Ltd. is a biopharmaceutical company that focuses on the research and development of innovative drugs for diabetes and obesity. Based in China and established in 2008 as Suzhou PegBio Medical Co.
, Ltd. , later was converted into a joint stock company in 2020. In 2025, the company changed its name to Hangzhou PegBio Medical Co. , Ltd.
upon redomiciling its registered office to Hangzhou. In May 2025, the company completed its initial public offering on the Hong Kong Stock Exchange. PegBio's drug pipeline focus on the development of long-acting peptide drugs for metabolic and endocrine diseases, including PB-119, PB-718, PB-401 and others. The company generates revenue mainly from commercialization of drugs and licensing agreements for pipeline products.
With funds raised from the IPO, the company plans to advance clinical trials and support further R&D to develop overseas commercialization strategies.
Current Investors
Tasly Pharmaceutical International Co., Ltd. , Oriza Holdings, Mingxin Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.pegbio.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.